Mibefradil API is a synthetic small-molecule calcium channel blocker with a distinctive pharmacological profile, particularly associated with T-type calcium channel inhibition. Mibefradil has been extensively studied in cardiovascular pharmacology and ion-channel research because of its effects on calcium-dependent cellular activity.
Mibefradil has the chemical formula C₂₉H₃₈FN₃O₃, a molecular weight of 495.63 g/mol, and CAS Number 116644-53-2. It is chemically related to the tetralin class of compounds and contains defined stereochemistry. The compound is also available in salt form as Mibefradil Dihydrochloride, providing an important form for pharmaceutical and analytical research.
Mibefradil was historically developed as a cardiovascular medicine for hypertension and chronic stable angina. Although its commercial use was discontinued in the United States, Mibefradil remains relevant in pharmaceutical research, calcium-channel studies, medicinal chemistry and drug-development programs.
Mibefradil API is suitable for qualified pharmaceutical and research applications where a well-characterized calcium-channel-active compound is required. Its distinctive interaction with calcium channels makes it particularly relevant to T-type calcium channel research, cardiovascular pharmacology and ion-channel studies.
The API can be incorporated into research programs involving:
Calcium channels play an important role in electrical signaling, muscle contraction and intracellular calcium regulation. T-type calcium channels are low-voltage-activated channels involved in the activity of various excitable cells.
Mibefradil is notable because of its activity against T-type calcium channels. This property has made it an important research compound for investigating calcium-channel physiology and pharmacology.
Research involving Mibefradil can help evaluate:
Mibefradil has an established history in cardiovascular drug development. Its original therapeutic development focused on its ability to influence calcium-dependent vascular and cardiac processes.
For pharmaceutical research organizations, Mibefradil API can therefore be relevant to studies involving:
Cardiovascular Pharmacology:
Research into calcium-channel modulation and cardiovascular signaling.
Ion-Channel Research:
Investigation of T-type calcium-channel activity.
Drug Discovery:
Evaluation of calcium-channel-modulating compounds.
Medicinal Chemistry:
Use as a structurally and pharmacologically characterized research compound.
Analytical Development:
Development and validation of analytical procedures for identification, purity and related substances.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |